P. J. Morris, Transplantation-a medical miracle of the 20th century, N Engl J Med, vol.351, pp.2678-2680, 2004.

J. Dantal, M. Hourmant, and D. Cantarovich, Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: Randomised comparison of two cyclosporin regimens, Lancet, vol.351, pp.623-628, 1998.

P. F. Halloran, Immunosuppressive drugs for kidney transplantation, N Engl J Med, vol.351, pp.2715-2729, 2004.

B. J. Nankivell and D. Kuypers, Diagnosis and prevention of chronic kidney allograft loss, Lancet, vol.378, pp.1428-1437, 2011.

B. J. Nankivell, R. J. Borrows, C. Fung, P. J. O'connell, R. Allen et al., The natural history of chronic allograft nephropathy, N Engl J Med, vol.349, pp.2326-2333, 2003.

M. Pascual, T. Theruvath, T. Kawai, N. Tolkoff-rubin, and A. B. Cosimi, Strategies to improve long-term outcomes after renal transplantation, N Engl J Med, vol.346, pp.580-590, 2002.

J. P. Soulillou and M. Giral, Controlling the incidence of infection and malignancy by modifying immunosuppression, Transplantation, vol.72, pp.89-93, 2001.

N. J. London, S. M. Farmery, E. J. Will, A. M. Davison, and J. P. Lodge, Risk of neoplasia in renal transplant patients, Lancet, vol.346, pp.403-406, 1995.

H. Ekberg, J. Griny-o, and B. Nashan, Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study, Am J Transplant, vol.7, pp.560-570, 2007.

H. Ekberg, H. Tedesco-silva, and A. Demirbas, Reduced exposure to calcineurin inhibitors in renal transplantation, N Engl J Med, vol.357, pp.2562-2575, 2007.

D. Abramowicz, D. C. Rial, M. Vitko, and S. , Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study, J Am Soc Nephrol, vol.16, pp.2234-2240, 2005.

T. A. Gonwa, D. E. Hricik, K. Brinker, J. M. Grinyo, and F. P. Schena, Sirolimus Renal Function Study G. Improved renal function in sirolimustreated renal transplant patients after early cyclosporine elimination, Transplantation, vol.74, pp.1560-1567, 2002.

J. I. Roodnat, L. B. Hilbrands, and . Hen-e-rj, 15-year follow-up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation, Transplantation, vol.98, pp.47-53, 2014.

P. Schnuelle, J. H. Van-der-heide, and A. Tegzess, Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen, J Am Soc Nephrol, vol.13, pp.536-543, 2002.

J. A. Butler, P. Roderick, M. Mullee, J. C. Mason, and R. C. Peveler, Frequency and impact of nonadherence to immunosuppressants after renal transplantation: A systematic review, Transplantation, vol.15, pp.769-776, 2004.

A. Asberg, T. Apeland, and A. V. Reisaeter, Long-term outcomes after cyclosporine or mycophenolate withdrawal in kidney transplantation-Results from an aborted trial, Clin Transplant, vol.27, pp.151-156, 2013.

P. Smak-gregoor, . Rgl, and G. Ligtenberg, Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: A randomized, prospective, multicenter study, J Am Soc Nephrol, vol.13, pp.1365-1373, 2002.

H. P. Tan, J. Donaldson, and A. Basu, Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up, Am J Transplant, vol.9, pp.355-366, 2009.

F. Vincenti, E. Ramos, and C. Brattstrom, Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation, Transplantation, vol.71, pp.1282-1287, 2001.

N. Pallet, E. I. Buchler, and M. , Long-term clinical impact of adaptation of initial tacrolimus dosing to CYP3A5 genotype, Am J Transplant, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01296771

B. L. Kasiske, H. A. Chakkera, T. A. Louis, and J. Z. Ma, A meta-analysis of immunosuppression withdrawal trials in renal transplantation, J Am Soc Nephrol, vol.11, pp.1910-1917, 2000.

W. H. Lim, S. J. Chadban, and P. Clayton, Human leukocyte antigen mismatches associated with increased risk of rejection, graft failure, and death independent of initial immunosuppression in renal transplant recipients, Clin Transplant, vol.26, pp.428-437, 2012.

K. J. Van-arendonk, E. A. King, and B. J. Orandi, Loss of pediatric kidney grafts during the "high-risk age window": Insights from pediatric liver and simultaneous liver-kidney recipients, Am J Transplant, vol.15, pp.445-452, 2015.

J. Ashton-chess, M. Giral, S. Brouard, and J. Soulillou, Spontaneous operational tolerance after immunosuppressive drug withdrawal in clinical renal allotransplantation, Transplantation, vol.84, pp.1215-1219, 2007.

E. Dugast, M. Chesneau, J. Soulillou, and S. Brouard, Biomarkers and possible mechanisms of operational tolerance in kidney transplant patients, Immunol Rev, vol.258, pp.208-217, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-02163167

D. E. Hricik, R. N. Formica, and P. Nickerson, Adverse outcomes of tacrolimus withdrawal in immune-quiescent kidney transplant recipients, J Am Soc Nephrol, vol.26, pp.3114-3122, 2015.

T. Akimova, B. M. Kamath, and J. W. Goebel, Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients, Am J Transplant, vol.12, pp.3449-3461, 2012.

G. Gupta, A. Regmi, and D. Kumar, Safe conversion from tacrolimus to belatacept in high immunologic risk kidney transplant recipients with allograft dysfunction, Am J Transplant, vol.15, pp.2726-2731, 2015.

F. Vincenti, L. Rostaing, and J. Grinyo, Belatacept and long-term outcomes in kidney transplantation, N Engl J Med, vol.374, pp.333-343, 2016.

M. D. Stegall, R. S. Gaston, F. G. Cosio, and A. Matas, Through a glass darkly: Seeking clarity in preventing late kidney transplant failure, J Am Soc Nephrol, vol.26, pp.20-29, 2015.